Table 2.
Grade 3–5 toxicities after dose-limiting toxicity observation period (courses 3 +) at least possibly attributable to tipifarnib
| Toxicity | No. of events (no. of patients) |
||
|---|---|---|---|
| Grade 3 | Grade 4 | Grade 5 | |
| Transaminase elevations | 1 (1) | ||
| Ataxia | 1 (1) | ||
| Low serum bicarbonate level | 1 (1) | ||
| Febrile neutropenia | 2 (2) | ||
| Infection with normal ANC or grade 1 or 2 neutropenia | 1 (1) | ||
| Neurology–Kluver-Bucy syndrome | 1 (1) | ||
| Leukopenia | 4 (2) | 1 (1) | |
| Lymphopenia | 11 (7) | ||
| Anemia | 2 (1) | ||
| Neutropenia | 3 (2) | 3 (2) | |
| Thrombocytopenia | 1 (1) | ||
| Hypokalemia | 2 (2) | ||
| Hyponatremia | 1 (1) | ||
Dosage was 125 mg/m2 per dose twice daily following radiation therapy. ANC indicates absolute neutrophil count.